Celsopupo | Istock | Getty ImagesZealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry.The new strategy, "Metabolic Frontier 2030," comes as Zealand shares have dropped 29% year to date as investors are betting the market will fragment, with fewer singular winners than they were 18 mo ...